Steps to regulate the pricing and quality of medical devices

1. At a Glance

• Dual regulatory architecture: NPPA (under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers) controls price; CDSCO (under MoHFW) controls quality, safety and performance [S1][S2][S3].
• Statutory basis: Drugs (Prices Control) Order (DPCO), 2013 for pricing and Drugs and Cosmetics Act, 1940 + Medical Devices Rules, 2017 for quality [S1][S3].
• UPSC relevance: classic GS-II/III intersection — governance of an essential-goods market, consumer protection, Aatmanirbhar Bharat in healthcare.

2. Why in the News

• PIB release dated 3 February 2026 by Department of Pharmaceuticals listed cumulative steps taken on price control + quality regulation of medical devices [S1].
• Reiterated that Bare Metal Stents, Drug Eluting Stents (incl. BVS/Biodegradable), IUDs and Condoms are the four medical devices in Schedule-I, DPCO 2013 [S1].

3. Background & Evolution

• 2013 — DPCO notified under Essential Commodities Act, 1955; NPPA empowered to fix ceiling prices for Schedule-I drugs [S1].
• Feb 2017 — Coronary stents (BMS, DES) brought under price control by NPPA [S2].
• Aug 2017 — Ceiling prices fixed for Orthopaedic Knee Implants; extended up to 15 November 2026 [S2].
• 31 Jan 2017 — Medical Devices Rules, 2017 notified; effective 1 January 2018 [S3].
• 2020–21 (COVID-19) — NPPA invoked Trade Margin Rationalisation (TMR) to cap margins on Pulse Oximeter, BP Monitor, Nebulizer, Digital Thermometer, Glucometer [S2].

4. Core Static Facts

• Pricing regulator: National Pharmaceutical Pricing Authority (NPPA), under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
• Quality regulator: Central Drugs Standard Control Organisation (CDSCO), under MoHFW [S3].
• Pricing law: DPCO 2013 (issued under Essential Commodities Act, 1955) [S1].
• Quality law: Drugs and Cosmetics Act, 1940 + Medical Devices Rules, 2017 [S3].
• Schedule-I devices (4): BMS; DES (incl. BVS/Biodegradable stents); IUDs; Condoms [S1].
• Ceiling prices (extant): BMS ₹10,692.69; DES ₹38,933.14 [S2].
• Classification (GHTF-aligned): Class A (low), B (low-moderate), C (moderate-high), D (high risk) [S3].
• QMS standard: ISO 13485 mandatory for manufacturing sites [S3].

5. Multi-Dimensional Analysis

Economic - TMR slashed MRPs of capped devices/medicines by up to ~90% in some categories [S2]. - Price caps incentivise volume but compress margins, affecting import-heavy device segments (India imports ~70%+ of medical devices).

Legal / Constitutional - DPCO 2013 is delegated legislation under Section 3 of the Essential Commodities Act, 1955 [S1]. - Medical Devices Rules 2017 are subordinate legislation under Drugs and Cosmetics Act, 1940 [S3].

Administrative - Bifurcated regulation (price vs. quality) across two ministries — coordination challenge. - Phased risk-based licensing (Class A/B by State Licensing Authority; C/D by Central Licensing Authority – CDSCO) [S3].

Scientific / Technological - Rules conform to Global Harmonisation Task Force (GHTF) framework, easing exports [S3]. - ISO 13485 alignment integrates Indian manufacturers with global supply chains [S3].

Social - Stent and knee-implant price caps directly aid cardiac/orthopaedic patients — large out-of-pocket health burden context [S2]. - IUD/condom price ceilings support family-planning equity [S1].

6. Recent Developments (last 12-18 months)

• 3 Feb 2026 — DoP reaffirmed NPPA's price-control architecture for medical devices [S1].
• 25 Mar 2025 — NPPA fixed ceiling prices of 928 scheduled formulations [S4].
• Knee-implant ceiling price extended up to 15 November 2026 [S2].

7. Prelims Hooks

• NPPA is under the Department of Pharmaceuticals, NOT under MoHFW [S1].
• DPCO 2013 derives authority from the Essential Commodities Act, 1955 [S1].
• Only 4 medical devices in Schedule-I DPCO 2013: BMS, DES, IUDs, Condoms [S1].
• Medical Devices Rules came into force on 1 January 2018 [S3].
• Classification under MDR 2017 follows the GHTF risk-based scheme (Class A-D) [S3].
• ISO 13485 is the mandated QMS standard [S3].
• Ceiling price of DES = ₹38,933.14; BMS = ₹10,692.69 [S2].
• TMR was first used on 42 non-scheduled anti-cancer drugs (526 brands) [S2].
• COVID-era TMR covered Pulse Oximeter, BP Monitor, Nebuliser, Digital Thermometer, Glucometer [S2].
• Knee implant price control: in force since August 2017, extended to 15 Nov 2026 [S2].
• CDSCO functions under the Drugs and Cosmetics Act, 1940 [S3].
• NLEM is issued by MoHFW, then incorporated into Schedule-I by DoP [S1].

8. Mains Relevance

• GS-II: Government policies/interventions in the health sector; issues relating to development & management of Health.
• GS-III: Indian Economy — regulation of essential commodities; Science & Tech — indigenous manufacturing.
• Probable stems: 1. "Critically examine the dual regulatory architecture for medical devices in India. Has it served the twin goals of affordability and quality?" 2. "Discuss the role of NPPA's Trade Margin Rationalisation as a price-control tool. How does it differ from ceiling-price fixation under Schedule-I, DPCO 2013?" 3. "Evaluate the Medical Devices Rules, 2017 in the context of global best practices and India's Aatmanirbhar Bharat in healthcare."

9. Related Topics to Study Next

• National List of Essential Medicines (NLEM) 2022 — feeds Schedule-I.
• PLI Scheme for Medical Devices (2020) — supply-side complement.
• National Medical Devices Policy 2023 — sectoral roadmap.
• Jan Aushadhi / PMBJP — affordability angle.
• Essential Commodities Act, 1955 — parent statute of DPCO.
• Ayushman Bharat (PM-JAY) — demand-side health financing.
• CDSCO & Drugs Controller General of India (DCGI) — institutional study.
• GHTF / IMDRF — global harmonisation context.

10. Common Errors / Trap Areas

• NPPA is under DoP / Ministry of Chemicals & Fertilizers, not MoHFW.
• DPCO is under Essential Commodities Act, not the Drugs and Cosmetics Act.
• Schedule-I medical devices are only four — easy to confuse with the larger list of notified devices under CDSCO.
• Trade Margin Rationalisation ≠ Ceiling Price — TMR applies to non-scheduled items; ceiling price to Schedule-I items.
• NLEM is finalised by MoHFW, not by NPPA (NPPA only fixes the price).

11. Sources

• [S1] Steps to regulate the pricing and quality of medical devices — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222523 — (tier: 1)
• [S2] Issue of high trade margins in essential medical devices / NPPA ceiling prices — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241169 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=1744388 — (tier: 1)
• [S3] Health Ministry Notifies Medical Devices Rules, 2017 — https://www.pib.gov.in/newsite/printrelease.aspx?relid=157955 — (tier: 1)
• [S4] NPPA fixed ceiling prices of 928 scheduled formulations (25.3.2025) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2116217 — (tier: 1)